Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study

Table 2

Characteristics of patients with measured MPA trough levels.

Patient	Age at start of MMF therapy (years)	Sex	Duration of MMF therapy (month)	MMF trough level (μg/mL)	MMF dose (mg/day)	SLEDAI at start of MMF therapy	Outcome of MMF	Adverse event	Achievement of LLDAS
1	32	Male	5	8.5	2,000	14	Withdrawal	Renal dysfunction	No
2	43	Female	16	8.3	2,000	12	Withdrawal	Infection (VZV meningitis)	Yes
3	38	Female	1	7.3	1,500	18	Dose decrease		No
4	43	Female	2	6.7	2,000	14	Withdrawal	Cytopenia	No
5	46	Male	20	6.6	2,000	6	Dose decrease		Yes
6	32	Female	4	6.3	2,000	14	Withdrawal	Infection (VZV meningitis)	No
7	32	Female	2	5.3	1,500	16	Dose decrease		No
8	18	Female	12	4.7	2,000	12	Dose decrease		No
9	38	Female	11	4	1,000	9	Continue		No
10	23	Female	3	3.5	2,000	8	Withdrawal	Alopecia	Yes
11	23	Female	1	3.1	2,000	20	Withdrawal	Cytopenia	No

MPA: mycophenolate acid; MMF: mycophenolate mofetil; SLEDAI: systemic lupus erythematosus disease activity index; LLDAS: lupus low disease activity state.